neptra
bayer animal health gmbh - florfenikol, hydroklorid terbinafin, mometason furoate - otologicals, kortikosteroider och antiinfectives i kombination - hundar - för behandling av akut hund extern otit eller akut försämring av återkommande öroninflammationer orsakade av blandade infektioner av känsliga stammar av bakterier känsliga för florfenikol (staphylococcus pseudintermedius) och svampar är känsliga för terbinafin (malassezia pachydermatis).
diklofenak sandoz 50 mg enterotablett
sandoz gmbh - diklofenaknatrium - enterotablett - 50 mg - laktosmonohydrat hjälpämne; makrogolglycerolhydroxistearat hjälpämne; diklofenaknatrium 50 mg aktiv substans; sorbinsyra hjälpämne - diklofenak
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinala stromaltumörer - antineoplastiska medel - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
adtralza
leo pharma a/s - tralokinumab - dermatit, atopisk - andra dermatologiska preparat - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
onglyza
astrazeneca ab - saxagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
efexor depot 150 mg depotkapsel, hård
upjohn eesv - venlafaxinhydroklorid - depotkapsel, hård - 150 mg - propylenglykol hjälpämne; venlafaxinhydroklorid 169,7 mg aktiv substans - venlafaxin
venlafaxin depot paranova 150 mg depotkapsel, hård
paranova läkemedel ab - venlafaxinhydroklorid - depotkapsel, hård - 150 mg - venlafaxinhydroklorid 169,7 mg aktiv substans; propylenglykol hjälpämne - venlafaxin
efexor depot 150 mg depotkapsel, hård
cross pharma ab - venlafaxinhydroklorid - depotkapsel, hård - 150 mg - venlafaxinhydroklorid 169,7 mg aktiv substans - venlafaxin
efexor depot 150 mg depotkapsel, hård
orifarm ab - venlafaxinhydroklorid - depotkapsel, hård - 150 mg - venlafaxinhydroklorid 169,7 mg aktiv substans - venlafaxin
efexor depot 150 mg depotkapsel, hård
medartuum ab - venlafaxinhydroklorid - depotkapsel, hård - 150 mg - venlafaxinhydroklorid 169,7 mg aktiv substans - venlafaxin